Literature DB >> 11962119

Inter-provincial variation in government drug formularies.

J P Grégoire1, P MacNeil, K Skilton, J Moisan, D Menon, P Jacobs, E McKenzie, B Ferguson.   

Abstract

In Canada, coverage for ambulatory prescription drug expenditures is provided to some groups by provincial drug plans through a provincial formulary. Little is known about the drugs provincial formularies give access to. We report the variation in availability of new drug molecules (NDM) across provincial formularies. We identified 108 NDM approved in Canada between 1991 and 1998. From each drug plan bulletin or formulary, we abstracted names of NDM listed as per 15 January 1999. We compared the level of listing across provinces using kappa coefficients. In the Quebec, BC, Manitoba and Saskatchewan formularies, more than 70% of the NDM were listed. In four provinces, this proportion was lower than 50%. In general, the agreement between formularies was poor. There is a wide variation across provinces in terms of NDM listed in the formularies. This variation reflects inter-provincial differences in the way drugs are selected for coverage.

Mesh:

Year:  2001        PMID: 11962119

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  16 in total

1.  A comparison of drug coverage in alberta before and after the introduction of the national common drug review process.

Authors:  John-Michael Gamble; Dean T Eurich; Jeffrey A Johnson
Journal:  Healthc Policy       Date:  2010-11

2.  Analysis of drug coverage before and after the implementation of Canada's Common Drug Review.

Authors:  John-Michael Gamble; Daniala L Weir; Jeffrey A Johnson; Dean T Eurich
Journal:  CMAJ       Date:  2011-10-24       Impact factor: 8.262

3.  Common Drug Review recommendations: an evidence base for expectations?

Authors:  Angela Rocchi; Elizabeth Miller; Robert B Hopkins; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

4.  Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.

Authors:  Jamie R Daw; Steven G Morgan
Journal:  Health Policy       Date:  2011-10-05       Impact factor: 2.980

5.  Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.

Authors:  Warren G Linley; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.981

6.  Breadth, Depth and Agreement among Provincial Formularies in Canada.

Authors:  Steve Morgan; Gillian Hanley; Colette Raymond; Régis Blais
Journal:  Healthc Policy       Date:  2009-05

7.  The politics of access to expensive drugs: INESSS and the innovative pharmaceutical industry.

Authors:  David Hughes
Journal:  Healthc Policy       Date:  2012-05

8.  6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.

Authors:  George P Browman; Braden Manns; Neil Hagen; Carole R Chambers; Anita Simon; Shane Sinclair
Journal:  J Oncol Pract       Date:  2008-01       Impact factor: 3.840

9.  Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.

Authors:  Warren G Linley; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

10.  Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.

Authors:  Virginie Demers; Magda Melo; Cynthia Jackevicius; Jafna Cox; Dimitri Kalavrouziotis; Stéphane Rinfret; Karin H Humphries; Helen Johansen; Jack V Tu; Louise Pilote
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.